BridgeBio Pharma, Inc. - 10-Q Filing
BridgeBio Pharma reports Q3 2026 results with revenue driven by product, license, and royalty segments.
Tickers: $BBIO
Read the full article at SEC EDGAR
Part of the story Aware, Inc. Reports Q3 2026 Results with Growing Recurring Revenue and Narrowing Losses (10 articles)